| Name | Proteome Sciences |
|---|---|
| Epic | PRM |
| Isin | GB0003104196 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 2.75p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £8.12 | Debt ratio | n/a |
| Shares in issue | 295.18 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -24.52 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.83 | 52-week high / low | 2.33p / 6.03p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Proteome Sciences |
|---|---|
| Address | Coveham House, Downside Bridge Road, Cobham, Surrey, United Kingdom, KT11 3EP |
| Telephone | +44 (0)1932 865065 |
| Website | http://www.proteomics.com |
| Director | Position |
|---|---|
| Mr Abdelghani Omari | CFO |
| Mr Roger Steven McDowell | Non-Executive Director |
| Ms Ursula Ney | Non-Executive Director |
| Mr Martin Diggle | Non-Executive Director |
| Dr. Ian Pike | Executive Director |
| Mr Christopher Pearce | Non-Executive Chairman |
| Mr Richard Dennis | Commercial Director |
| Dr Mariola Sohngen | Director & CEO |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 4.22 | 4.22 | 4.22 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 7.29 | 5.54 | 5.49 |
| Inventory / work in progress | 0.84 | 0.9 | 1.09 |
| Trade and other receivables | 0.95 | 1.44 | 0.6 |
| Cash and equivalents | 2.03 | 3.99 | 2.39 |
| Other current assets and asset held for resale | 0.35 | 0.56 | 0.48 |
| Total of all assets | 11.46 | 12.43 | 10.04 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 12.47 | 12.49 | 11.72 |
| Long term liabilities | 2.05 | 0.79 | 1.1 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 14.52 | 13.28 | 12.82 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | -3.07 | -0.84 | -2.77 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 2.95 | 2.95 | 2.95 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -72.94 | -70.54 | -72.01 |
| Share premium account | 51.47 | 51.47 | 51.47 |
| Total equity | -3.07 | -0.84 | -2.77 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -1.62 | 1.73 | 0.41 |
| Pre-tax profit | -2.42 | 1.25 | 0.12 |